A Phase 3 interventional study of Dexamethasone and Bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag G.m.b.H. Completed at 40 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-15.
Sponsored by Janssen-Cilag G.m.b.H (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.
Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 81st largest by enrollment of the 373 interventional ones that give a count, is one of 13 that started in 2009, is one of 53 in phase 3, and was the 84th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
University of Miami · Sites in United States
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
381 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 273 · Phase 3 57 · Phase 4 9
First in 1995; this study’s year is marked. 13 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 45 across the 373 interventional studies. Of the 225 that completed or were terminated, 118 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 381 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag G.m.b.H, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag G.m.b.H is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 61st largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2009, is one of 35 in phase 3, and was the 25th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
27 of the studies testing dexamethasone in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00572169Phase 3University of ArkansasUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | 2027-08 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT05560399Icahn School of Medicine at Mount SinaiA Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 381 studies testing dexamethasone in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare bortezomib, dexamethasone and cyclophosphamide to bortezomib and dexamethasone alone for primary refractory or relapsed multiple myeloma.
This is a prospective, multi-centre, randomized (the study drug is assigned by chance), controlled, open-label (all people involved in the study know the identity of the assigned drug), parallel (each group of patients will be treated at the same time) group phase III study to determine the efficacy of the standard therapy of bortezomib and low dose dexamethasone in combination with or without continuous low dose oral cyclophosphamide for primary refractory or relapsed myeloma patients (1st - 3rd relapse). The study will consist of screening period, which may last from day -14 until day -1 before application of the first dose of bortezomib (on cycle 1, day 1), treatment phase begins on cycle 1 day 1 and continues until completion or discontinuation of all study drugs and follow-up phase. All patients will be followed up after end of treatment regardless of their response. Eligible patients will be randomized in 1:1 ratio to receive either treatment arms (Group A: receiving bortezomib plus dexamethasone or Group B receiving bortezomib plus dexamethasone plus cyclophosphamide). Patients will receive up to eight 3-weeks treatment cycles, unless they experience either unacceptable toxicity or if the patients request to withdraw from the study. The maximum number of cycles is dependent on patient response and investigator's discretion. It is recommended that patients with a confirmed complete response (CR) receive 2 additional cycles beyond a confirmation. Patients who do not achieve a CR but a partial response will receive a total of 8 cycles. For patients achieving stable disease it is within the investigator's discretion to continue study treatment beyond 6 cycles, after discussion with the sponsor. After completion of treatment the patients will be followed up every 12 weeks for up to 72 weeks. If the study is still ongoing a further follow up period will be done every 26 weeks until study end, or until the patient reaches progressive disease or start of alternative anti-myeloma therapy, if earlier. In case progressive disease (PD) has already been established during the treatment phase the patients will not enter the follow-up phase. In case of PD or start of alternative anti-myeloma treatment before the end of study the follow-up phase will be discontinued for the patient but the date of death of the patient will be documented (if applicable) before the end of study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle.
Drug: Dexamethasone · Drug: Bortezomib
Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
Drug: Dexamethasone · Drug: Bortezomib · Drug: Cyclophosphamide
Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
Time to Progression of Disease
'Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.
Time frame: From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)
Progression-Free Survival (PFS)
PFS is defined as time from randomization to myeloma progression according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of ≥25 percent from lowest response level in Serum M-component and/or (the absolute increase must be ≥0.5 g/dL) Urine M-component and/or (the absolute increase must be ≥200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be ≥10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65mmol/L) that can be attributed solely to the plasma cell proliferative disorder. PFS included disease progression as well as death.
Time frame: From the date of randomization until the disease progression or participant's death from any cause whichever occured first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)
Overall Survival (OS)
Time interval in months time from randomisation to death from any cause.
Time frame: From the date of randomization until Month 49
Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria
Percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) is reported in the below table. IMWG criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescencec; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 hour.
Time frame: Up to 46 days after last bortezomib dose, or as soon as possible after early discontinuation of study treatment or before start of alternative anti-myeloma therapy
The study was conducted between 23 December 2008 and 10 January 2013 and recruited patients from 42 study centers in Germany.
| Milestone | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| Started | 46 | 47 |
| Intent-to-treat participants | 43 | 47 |
| Completed | 14 | 15 |
| Not completed | 32 | 32 |
| Withdrew: Adverse event | 16 | 15 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Complete response | 0 | 1 |
| Withdrew: Stable disease | 1 | 2 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Non compliance | 0 | 1 |
| Withdrew: Reason not specified | 3 | 4 |
| Withdrew: Data not available | 1 | 2 |
| Milestone | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| Started | 26 | 31 |
| Completed | 2 | 0 |
| Not completed | 24 | 31 |
| Withdrew: Death | 0 | 4 |
| Withdrew: Other | 0 | 3 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Progression/relapse | 22 | 24 |
'Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of \>=25% from lowest level in Serum M-component or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]); Urine M component or (the absolute increase must be \>=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase \>10 mg/dL. Bone marrow plasma cell percentage \>=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.
| Months | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| Time to Progression of Disease | 12.6 (9.83 to 14.43) | 9.9 (8.60 to 11.40) |
PFS is defined as time from randomization to myeloma progression according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of ≥25 percent from lowest response level in Serum M-component and/or (the absolute increase must be ≥0.5 g/dL) Urine M-component and/or (the absolute increase must be ≥200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be ≥10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65mmol/L) that can be attributed solely to the plasma cell proliferative disorder. PFS included disease progression as well as death.
| Months | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| Progression-Free Survival (PFS) | 12.6 (9.83 to 14.43) | 9.9 (8.60 to 11.40) |
Time interval in months time from randomisation to death from any cause.
| Months | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | 41.50 (24.87 to NA) |
Percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) is reported in the below table. IMWG criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescencec; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100mg per 24 hour.
| Percentage of participants | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria | 74.4 (NA to NA) | 70.2 |
Collected over Approximately 5 years. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vd (Bortezomib + Dexamethasone) | — | 15/46 (32.6%) | 43/46 (93.5%) |
| Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) | — | 14/47 (29.8%) | 46/47 (97.9%) |
| Event | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| PneumoniaInfections and infestations | 4/46 | 4/47 |
| Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/46 | 0/47 |
| DiverticulitisInfections and infestations | 2/46 | 0/47 |
| SepsisInfections and infestations | 2/46 | 0/47 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/46 | 1/47 |
| SyncopeNervous system disorders | 0/46 | 2/47 |
| InfectionInfections and infestations | 1/46 | 0/47 |
| ConstipationGastrointestinal disorders | 1/46 | 1/47 |
| Ileus paralyticGastrointestinal disorders | 1/46 | 0/47 |
| Inguinal hernia, obstructiveGastrointestinal disorders | 1/46 | 0/47 |
| Event | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 17/46 | 18/47 |
| FatigueGeneral disorders | 13/46 | 18/47 |
| DiarrhoeaGastrointestinal disorders | 11/46 | 17/47 |
| ConstipationGastrointestinal disorders | 10/46 | 13/47 |
| AnaemiaBlood and lymphatic system disorders | 12/46 | 6/47 |
| NauseaGastrointestinal disorders | 7/46 | 11/47 |
| NasopharyngitisInfections and infestations | 3/46 | 11/47 |
| Oedema peripheralGeneral disorders | 7/46 | 10/47 |
| PolyneuropathyNervous system disorders | 7/46 | 9/47 |
| Peripheral sensory neuropathyNervous system disorders | 3/46 | 9/47 |
Number of Intent-to-treat (ITT) participants were included in Baseline analysis. Out of 93 randomized participants (Vd=46; Vcd=47), follow-up data on treatment response was not available for 3 participants, so, they were excluded from the Intent-to-treat (ITT) analysis data set and so, ITT included 90 participants (Vd=43; Vcd=47).
| Age, Continuous(Years) | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) | Total |
|---|---|---|---|
| Mean | 68 ± 10 | 71 ± 7 | 69 ± 9 |
| Sex: Female, Male(Participants) | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) | Total |
|---|---|---|---|
| Female | 18 | 21 | 39 |
| Male | 25 | 26 | 51 |
| Race/Ethnicity, Customized(Participants) | Vd (Bortezomib + Dexamethasone) | Vcd (Bortezomib + Low-dose Dexamethasone + Cyclophosphamide) | Total |
|---|---|---|---|
| Caucasian | 42 | 47 | 89 |
| African | 1 | 0 | 1 |
The record gives a start of Jan 2009, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Bortezomib